What is the dosage of Herceptin in clinical trials?

Primary loading dose: It is recommended that the initial loading amount of this product is 4mg kg. Intravenous infusion over 90 minutes.

Patients should be observed for fever, chills, or other infusion-related symptoms (see Adverse Reactions). Stopping the infusion can control these symptoms, and the infusion can be continued when symptoms disappear.

Maintenance dose: It is recommended that the weekly dosage of this product is 2mg kg. If the initial loading is tolerated, this dose can be given intravenously over 30 minutes. Maintain** until disease progression.

Breast Cancer Adjuvant**:

Start trastuzumab after completion of all chemotherapy**. The regimen of trastuzumab is 8 mg kg as an initial loading followed by 6 mg kg maintenance every 3 weeks as an IV infusion over approximately 90 minutes.

A total of 17 doses (52 weeks of treatment) were administered.

Rapid oral algorithm for the dosage of several commonly used rescue drugs in pediatrics.

In order to improve the accuracy of pediatric drug dosage, only milligrams are generally prescribed in the doctor's order, and they need to be converted into milliliters when using, which is easy to make mistakes when using emergency medication. The rapid oral algorithm of several commonly used drug doses is summarized.

1) Cediran injection g 2ml sticks, multiply the required milligrams by 5 to get the required milliliters. If you want to use it, you need to aspirate ml.

2) There are 2 commonly used dosage forms of aminophylline: 250mg 2ml specification, the required milligrams can be multiplied to get the required milliliter, if 25m g is used, 02ml, 500m g 2ml specification, multiply the required milligrams to get the number of milliliters, if you want to use 30mg, you need to aspirate 0

12ml。3) Sodium phenobarbital is 100 mg stick, powder, which can be solventized into 100 mg ml, 100 mg 2ml, 100mg 5ml according to the required usage and dosage. For 20 mg, 100 mg 5ml can be used to convert 20 mg ml, and if 50 mg is used, 100 mg 2 ml can be used.

4) Promethazine 25 mg ml multiply by 0 by the required number of milligrams04 can get the number of milliliters. If 15 mg is used, aspiration is required.

Proper storage can be used.

Deputy Chief Physician of Shanghai Tenth People's Hospital-Department of Nail Lactology-Li Zhe.

Metastatic breast cancer: This product is suitable for metastatic breast cancer with HER2 overexpression: metastatic breast cancer that has received 1 or more chemotherapy regimens as a single drug**In combination with paclitaxel or docetaxel in patients with metastatic breast cancer naïve to chemotherapy.

Adjuvant breast cancer**: This single agent is suitable for the adjuvant treatment of HER2-overexpressing breast cancer after surgery, adjuvant chemotherapy with anthracycline-containing antibiotics and radiotherapy (if applicable). Metastatic gastric cancer:

This product is suitable for patients with metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not received HER2 overexpression for metastatic disease** in combination with capecitabine or 5-fluorouracil and cisplatin. Trastuzumab should only be used in patients with metastatic gastric cancer with HER2 overexpression, defined as IHC3+ or IHC2+ FISH+ results using validated assays.

In clinical studies, the serum concentration of trastuzumab increased by a fold from baseline when trastuzumab was combined with paclitaxel. In drug-drug interaction studies, the pharmacokinetics of docetaxel and paclitaxel did not change when combined with trastuzumab. Drug interactions between trastuzumab and paclitaxel were evaluated in trial BO15935 with no significant interactions between the two drugs.

In Trial M77004, the pharmacokinetics of trastuzumab versus doxorubicin + paclitaxel** and weekly paclitaxel** in women with HER2-positive metastatic breast cancer were evaluated with no significant interactions with paclitaxel and doxorubicin (and their major metabolites). Trial JP16003 is a single-arm trial in Japanese female patients with HER2-positive metastatic breast cancer. In this trial, there were no significant drug interactions between trastuzumab and doxorubicin.

Trial JP19959 is a substudy of the TOGA trial conducted in Japanese male and female patients with advanced gastric cancer to investigate the pharmacokinetics of capecitabine and cisplatin with or without trastuzumab. The results of this mini-substudy suggest that the pharmacokinetics of capecitabine (and its metabolites) are not affected by the combination of cisplatin or cisplatin + trastuzumab. The data also suggest that the pharmacokinetics of cisplatin is not affected by the combination of capecitabine or the combination of capecitabine + trastuzumab.

The pharmacokinetics of trastuzumab were not evaluated in this trial.